Get started
Author

Young Jung

Observed institution: AstraZeneca (Canada)
OpenAlex ID: A5122812239
55Real-world characteristics, costs, and outcomes with best supportive care vs anticancer therapy in patients with advanced BTC
2026 · Midhun Malla, Susanne Radke, et al. · The Oncologist
56Global Patient Interviews Exploring the Journey from Symptoms to Diagnosis and Treatment Initiation in Biliary Tract Cancer
2026 · Jennifer Knox, Young Jung, et al. · The Oncologist
52Treatment patterns among patients with extrahepatic cholangiocarcinoma with autoimmune conditions: a retrospective study
2026 · Sumera I Ilyas, Milind M Javle, et al. · The Oncologist
48Factors associated with resectable and unresectable biliary tract cancer using claims and electronic health records
2026 · Midhun Malla, Flavio Rocha, et al. · The Oncologist
50Real-world characteristics and outcomes of durvalumab + gemcitabine + cisplatin in patients with cholangiocarcinoma in the US
2026 · Nilofer S Azad, Milind M Javle, et al. · The Oncologist
Real-world (rw) outcomes of durvalumab plus gemcitabine and cisplatin (D + GemCis) or GemCis in patients (pts) with advanced biliary tract cancer in the US.
2026 · Vaibhav Sahai, James J. Harding, et al. · Journal of Clinical Oncology
PDF
Works count: 6
Citation count:
H-index:
I10-index:
Year
Topic
Type